Fenofibrate regardless of meals will be listed next month

Yuhan's Fenowell is Fenofibrate 145mg

It costs 339 won per tablet, which is cheaper than the existing medicine

Fenofibrate tablets, which can be taken regardless of meals, will be listed for the first time in Korea.

 

Fenofibrate is a drug used for primary hyperlipidemia.

 

Existing drugs should be administered after meals.

 

Therefore, the newly registered product is expected to improve the convenience of patients.

 

According to the MOHW on the 24th, Yuhan's Fenowell 145mg will be listed at 339 won on the 1st of next month.

 

Fenowell 145 mg is the only Fenofibrate tablet with 145 mg.

 

In addition, it has the advantage of oral administration regardless of meals.

 

It is used for primary hyperlipidemia such as hypercholesterolemia (Type IIa), hypercholesterolemia and hypertriglycerideemia (Type IIb, Type III), and hypertriglycerideemia (Type IV).

 

Adults can take only one tablet (145 mg) a day regardless of meals.

 

Existing Fenofibrate formulations should be administered orally immediately after meals at a dose of 160 mg.

 

It is considered absorption in the stomach.

 

Fenowell 145mg is absorbed by the gastrointestinal tract so it can be taken regardless of food intake.

 

The original is Abbott's Tricor, which was approved by the US FDA in 2004.

 

It is a drug that has not been introduced in Korea.

 

Fenofibrate cholins can also be taken regardless of meal.

 

There is TG Fenon, Daewon Pharmaceutical of Fenocholine by Korea Pharma.

 

Hanmi's Fenocid can be taken regardless of meal.

 

These items are now leading the market with this convenience.

 

Yuhan preoccupied the related domestic market in November 2020 with the approval of Fenowell 145mg.

 

In the same month, GC Pharma was also approved for the same product, Neofeno 145 mg.

 

This product is commissioned by Yuhan.

 

GC Pharma's product is not listed this time, so Yuhan is the only one that sells it with 145mg tablets.

 

The price of 339 won is also cheaper than the existing tablets.

 

Currently, the upper limit of 160mg of Fenofibrate tablets ranges from 316 won to 356 won.

 

Excluding three of these products, the remaining 18 products are listed at the highest price of 356 won.

 

Analysts say that despite the improved convenience of taking drugs, the price is also cheaper, which may serve as a factor for replacing prescriptions.

 

GC Pharma's Lipidil supra, a leading item in the market, recorded 16.5 billion won in outpatient prescriptions last year.

 

The total domestic market is also worth 90 billion won.

 

Attention is being paid to whether the new limited product, which upgraded existing products, will be able to change its competitive structure in the market.